Ann: Investor Presentation, page-6

I'm also in it for the long haul, so I'm not worried about the short term price movement. Hopefully updates on patient recruitment numbers will boost the share price.

And I know most on this thread won't agree (and I keep banging on about it), but some pre-clinical studies demonstrating efficacy in another disease group with a larger TAM will definitely push the SP in the right direction. I think it'll generate some wider interest in the market (and with instos) and de-risk the proposition. They did say that, when this trial is set up, they will focus some energy on another indication, so hopefully we're not too far way from that.